Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
about
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Achondroplasia: Development, pathogenesis, and therapy.Point-of-care devices: the next frontier in personalized chemotherapy.Mechanisms of Mendelian dominance.Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.Disease Variants of FGFR3 Reveal Molecular Basis for the Recognition and Additional Roles for Cdc37 in Hsp90 Chaperone System.Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors.NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 3 in apo state and in complex with inhibitor PD173074.CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
P2860
Q38776411-253C784E-7301-411D-8596-4446F69209C2Q39041957-D8BE687F-71D1-4D6B-967D-37C095EED62EQ42353648-6258F488-C312-462D-8A83-79B0E77B0011Q48326258-708667AF-6FAE-4452-ADC0-CCCE07430FB2Q49456418-A612C9ED-F5A6-4C8B-877F-AB920D5FD0D9Q50421963-1AF7CEFB-E180-4EB3-BE93-D09A87161C76Q51070856-EAAA5AA2-60B2-4FF2-A239-B86EC0CDE82DQ52340750-2EA746E5-396D-40BE-904C-77B55EE9AFB4Q58695446-3BAF31D2-D816-47F1-9FAD-799DAE13CBB7
P2860
Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Landscape of activating cancer ...... to inhibitors in clinical use.
@en
Landscape of activating cancer ...... to inhibitors in clinical use.
@en-gb
Landscape of activating cancer ...... to inhibitors in clinical use.
@nl
type
label
Landscape of activating cancer ...... to inhibitors in clinical use.
@en
Landscape of activating cancer ...... to inhibitors in clinical use.
@en-gb
Landscape of activating cancer ...... to inhibitors in clinical use.
@nl
prefLabel
Landscape of activating cancer ...... to inhibitors in clinical use.
@en
Landscape of activating cancer ...... to inhibitors in clinical use.
@en-gb
Landscape of activating cancer ...... to inhibitors in clinical use.
@nl
P2093
P2860
P50
P356
P1154
2-s2.0-84966457637
P1433
P1476
Landscape of activating cancer ...... to inhibitors in clinical use.
@en
P2093
Camilla S M Pang
Chris Phillips
Gary S Thomson
Harshnira Patani
Jason Breed
Matilda Katan
Mina Edwards
Nethaji Thiyagarajan
Paul Ashford
P2860
P304
24252-24268
P356
10.18632/ONCOTARGET.8132
P407
P5530
P577
2016-03-16T00:00:00Z
P6179
1005845374